Results 21 to 30 of about 5,710 (181)

Effect of evolocumab on cholesterol synthesis and absorption[S]

Journal of Lipid Research, 2016
The effects of cholesterol-lowering drugs, including those that reduce cholesterol synthesis (statins) and those that reduce cholesterol absorption (ezetimibe), on cholesterol absorption and synthesis are well understood. Proprotein convertase subtilisin/
Matthew Peach, Ren Xu, Dan Fitzpatrick, Lisa Hamilton, Ransi Somaratne, Robert Scott, Scott M. Wasserman, C. Stephen Djedjos   +7 more
doaj   +1 more source

Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study [PDF]

The Korean Journal of Internal Medicine
Background/Aims Achieving rapid reduction of low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL in patients with acute myocardial infarction (AMI) can be challenging with statins alone.
Yongcheol Kim, Ji Woong Roh, Oh-Hyun Lee, Seok-Jae Heo, Eui Im, Deok-Kyu Cho, Byeong-Keuk Kim   +6 more
doaj   +1 more source

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia [PDF]

, 2020
BACKGROUND Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels.
Hamer, Andrew, Mach, François, Kastelein, John JP, Santra, Saikat, Gaudet, Daniel, Descamps, Olivier S., Santos, Raul D, Bergeron, Jean, Descamps, Olivier S, Wiegman, Albert, Hovingh, G. Kees, HAUSER-RCT Investigators, Kastelein, John J.P., Greber-Platzer, Susanne, Stefanutti, Claudia, Kurtz, Christopher E., Chir, B., Bartuli, Andrea, Santos, Raul D., Sokal, Etienne, Szamosi, Tamás, Luirink, Ilse, Ruzza, Andrea, Bridges, Ian, Kastelein, John J. P., Hovingh, Kees   +25 more
core   +1 more source

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Cardiology and Therapy, 2020
Introduction Clinicians, payers, guideline committees, and policymakers support the use of high-intensity statins in patients at high risk for complications of cardiovascular disease (CVD).
Michael J. Koren, Peter H. Jones, Jennifer G. Robinson, David Sullivan, Leslie Cho, Thomas Hucko, J. Antonio G. Lopez, Alex N. Fleishman, Ransi Somaratne, Erik Stroes   +9 more
doaj   +1 more source

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear.
Hong-Fei Wang, Hong-Fei Wang, Yu-Cheng Mao, Yu-Cheng Mao, Xin-Yi Xu, Xin-Yi Xu, Si-Yu Zhao, Si-Yu Zhao, Dan-Dan Han, Dan-Dan Han, Shi-Yao Ge, Shi-Yao Ge, Kai Song, Kai Song, Chang Geng, Chang Geng, Qing-Bao Tian, Qing-Bao Tian   +17 more
doaj   +1 more source

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Journal of Cardiovascular Development and Disease, 2022
Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially ...
Tomoaki Okada, Toru Miyoshi, Masayuki Doi, Kazumasa Nosaka, Ryu Tsushima, Satoko Ugawa, Wataru Takagi, Masahiro Sogo, Masahiko Takahashi, Hiroshi Ito   +9 more
doaj   +1 more source

Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia

, 2022
Background: Evolocumab is a fully human monoclonal antibody inhibitor of PCSK9 approved for lowering low-density lipoprotein cholesterol in adults and pediatric patients with familial hypercholesterolemia (FH). The cognitive safety of evolocumab has been
Hovingh, G. Kees, Hamer, Andrew, Mach, François, Raal, Frederick J., Maruff, Paul, Gaudet, Daniel, Gaudet, Isabelle, Pierre, Julie St, Schembri, Adrian, Santos, Raul D., Bergeron, Jean, Ruzza, Andrea, Bridges, Ian, Kastelein, John J. P., Wiegman, Albert   +14 more
core   +2 more sources

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

BMJ Open, 2022
Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical
Ken Bassett, James Wright, Leire Leache, Luis Carlos Saiz, Juan Erviti, Thomas L Perry, Mohamed Ben-Eltriki, Ciprian Jauca, Marta Gutiérrez-Valencia   +8 more
doaj   +1 more source

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia [PDF]

, 2016
BACKGROUND: Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in patients with heterozygous familial hypercholesterolemia (HeFH) as ...
Raal, Frederick J., STEFANUTTI, Claudia, Kees Hovingh, G., Lira, Armando, Dent, Ricardo, Somaratne, Ransi, Descamps, Olivier, Sullivan, David, Bridges, Ian   +8 more
core   +2 more sources

Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials. [PDF]

Diabetes Obes Metab
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Zayed JA, Al-Awamleh NA, Hamad M, Hdaib MIM, Ayesh H.   +4 more
europepmc   +2 more sources